rs2231142
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The ABCG2 421 C > A (Q141K) polymorphism may be an important predictor of response and survival in HRPC patients treated with docetaxel-based chemotherapy.
|
17062685 |
2006 |
rs77375493
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
|
20966544 |
2010 |
rs775174909
|
|
|
0.010 |
GeneticVariation |
BEFREE |
513 patients with castrate-resistant prostate cancer (CRPC), including 284 patients who received radiotherapy, 229 patients without radiotherapy and 152 healthy individuals were genotyped for five polymorphisms in DNA excision repair genes:ERCC1 N118N (500C>T), XPD K751Q (2282A>C), XRCC1 R194W (685C>T), XRCC1 R399Q (1301G>A) and PARP1 V762A(2446T>C).
|
20495366 |
2010 |
rs886054499
|
|
|
0.010 |
GeneticVariation |
BEFREE |
513 patients with castrate-resistant prostate cancer (CRPC), including 284 patients who received radiotherapy, 229 patients without radiotherapy and 152 healthy individuals were genotyped for five polymorphisms in DNA excision repair genes:ERCC1 N118N (500C>T), XPD K751Q (2282A>C), XRCC1 R194W (685C>T), XRCC1 R399Q (1301G>A) and PARP1 V762A(2446T>C).
|
20495366 |
2010 |
rs2234693
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
rs700519
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
rs747099645
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
rs9340799
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Serum LDH may be a promising predictor of prognosis, and the ABCB1 C3435T polymorphism may be a genetic predictor of the severity of leukocytopenia in patients with CRPC treated with DEC.
|
21706123 |
2012 |
rs1057519864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
AR F876L is sufficient to confer resistance to ARN-509 and enzalutamide in in vitro and in vivo models of castration-resistant prostate cancer (CRPC).
|
23779130 |
2013 |
rs1004467
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
rs12422149
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT).
|
23896625 |
2013 |
rs4149117
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT).
|
23896625 |
2013 |
rs6162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
rs6163
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
rs743572
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox regression analysis for these SNPs showed an association of risk of progression to CRPC with the rs743572 genotype (p = 0.02, odds ratio [OR] 0.43, 95 % confidence interval [CI] 0.22-0.85).
|
22714708 |
2013 |
rs137852578
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.
|
25432158 |
2015 |
rs2208532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
rs5472
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
|
26428930 |
2015 |
rs676033
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
rs1057519864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Using cell line models of castration-resistant prostate cancer (CRPC), we determined that cellular androgen content influences enzalutamide agonism of mutant F877L AR.
|
27276681 |
2016 |
rs1057519864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The consequence of suppressing AR-F876L may then abrogate AR-F876L mediated CRPC cell proliferation and metastasis.
|
27233475 |
2016 |
rs1395
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
rs1799811
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
rs7602171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |